Profile data is unavailable for this security.
About the company
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED is a Hongkong-based investment holding company. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The Company mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.
- Revenue in HKD (TTM)264.79bn
- Net income in HKD4.17bn
- Incorporated2007
- Employees72.99k
- LocationChina Resources Pharmaceutical Group LtdRoom 4104-05, 41F,China Resources BuldngNo. 26, Harbour Road, Wan Chai Hong KongHKG
- Phone+852 25938991
- Fax+852 25938992
- Websitehttps://www.crpharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Medical System Holdings Ltd | 8.67bn | 2.60bn | 18.22bn | 5.70k | 7.01 | 1.08 | 6.44 | 2.10 | 1.06 | 1.06 | 3.54 | 6.85 | 0.4517 | 3.42 | 6.19 | 1,520,953.00 | 13.44 | 18.44 | 15.70 | 21.14 | 76.24 | 75.47 | 29.76 | 34.26 | 3.98 | -- | 0.0772 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
| China Meheco Group Co Ltd | 37.95bn | 1.00bn | 18.45bn | 8.39k | 18.44 | 1.46 | -- | 0.4863 | 0.6183 | 0.6183 | 23.44 | 7.83 | 0.9224 | 4.58 | 2.28 | 4,180,309.00 | 2.96 | 3.40 | 6.72 | 7.76 | 11.22 | 14.15 | 3.21 | 2.93 | 1.22 | 8.89 | 0.335 | 28.22 | 3.28 | 4.60 | 42.45 | -7.46 | 6.72 | -1.02 |
| Suzuken Co Ltd | 119.18bn | 1.39bn | 18.68bn | 13.43k | 14.19 | 0.9128 | 10.22 | 0.1567 | 336.97 | 336.97 | 28,802.96 | 5,236.47 | 1.82 | 12.94 | 4.05 | 176,574,900.00 | 2.12 | 1.77 | 6.33 | 4.64 | 7.75 | 8.05 | 1.17 | 0.9199 | 0.9883 | -- | 0.00 | 31.44 | 3.38 | 1.74 | 41.35 | 1.57 | 17.43 | 5.92 |
| Alfresa Holdings Corporation | 142.14bn | 1.60bn | 24.24bn | 11.77k | 14.57 | 0.9574 | 10.64 | 0.1705 | 163.14 | 163.14 | 14,454.60 | 2,483.23 | 1.92 | 15.08 | 4.12 | 240,225,700.00 | 2.17 | 2.47 | 6.17 | 6.52 | 7.24 | 7.34 | 1.13 | 1.24 | 1.03 | -- | 0.0607 | 33.25 | 4.27 | 0.7057 | -19.87 | -6.24 | 15.54 | 7.89 |
| Medipal Holdings Corp | 176.29bn | 1.87bn | 27.46bn | 12.80k | 14.04 | 0.8939 | 8.39 | 0.1557 | 175.85 | 175.85 | 16,560.73 | 2,761.44 | 1.91 | 16.34 | 4.40 | 274,130,900.00 | 2.60 | 2.62 | 7.75 | 7.32 | 6.85 | 6.90 | 1.37 | 1.34 | 1.01 | -- | 0.00 | 27.22 | 2.10 | 1.32 | 31.89 | 2.21 | -15.04 | 6.23 |
| China National Medicines Corp Ltd | 54.74bn | 2.37bn | 29.60bn | 3.14k | 12.48 | 1.69 | -- | 0.5406 | 2.90 | 2.90 | 67.05 | 21.51 | 1.61 | 11.21 | 6.58 | 16,122,340.00 | 7.57 | 7.32 | 14.41 | 15.03 | 7.63 | 8.15 | 4.70 | 4.31 | 1.77 | -- | 0.1271 | 30.04 | 9.23 | 5.11 | 9.26 | 8.85 | 1.84 | 16.38 |
| EBOS Group Ltd | 65.48bn | 1.33bn | 31.30bn | 5.20k | 23.34 | 2.54 | 14.98 | 0.478 | 1.47 | 1.47 | 72.21 | 13.51 | 1.90 | 8.79 | 8.35 | 2,671,388.00 | 3.94 | 4.32 | 6.35 | 7.62 | 12.49 | 11.47 | 2.08 | 1.98 | 0.7358 | 6.79 | 0.4402 | 76.77 | 14.00 | 11.86 | 25.06 | 13.04 | 11.11 | 10.05 |
| China Resources Pharmaceutical Group Ltd | 264.79bn | 4.17bn | 35.06bn | 72.99k | 8.41 | 0.7049 | 2.96 | 0.1324 | 0.6638 | 0.6638 | 42.15 | 7.92 | 1.06 | 7.06 | 3.84 | 3,627,920.00 | 3.36 | 3.02 | 12.72 | 11.35 | 15.67 | 15.72 | 3.18 | 2.87 | 1.09 | 8.70 | 0.412 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| Jointown Pharmaceutical Group Co Ltd | 160.71bn | 2.35bn | 35.32bn | 30.10k | 15.27 | 1.33 | -- | 0.2198 | 0.5469 | 0.5469 | 37.57 | 6.28 | 1.53 | 8.05 | 3.96 | 4,934,201.00 | 2.31 | 3.01 | 7.85 | 9.72 | 7.68 | 8.24 | 1.50 | 1.98 | 0.9782 | 3.50 | 0.5673 | 34.73 | 6.92 | 11.50 | 4.88 | 14.16 | -10.39 | 39.14 |
Data as of May 10 2024. Currency figures normalised to China Resources Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD
5.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2023 | 86.98m | 1.39% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 66.05m | 1.05% |
| BC Investment Management Corp.as of 31 Mar 2023 | 43.25m | 0.69% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 36.80m | 0.59% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 35.43m | 0.56% |
| BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 16.92m | 0.27% |
| The Caisse de d�p�t et placement du Qu�becas of 31 Dec 2022 | 15.77m | 0.25% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 14.69m | 0.23% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2023 | 12.79m | 0.20% |
| Principal Global Investors (Hong Kong) Ltd.as of 30 Jun 2023 | 12.42m | 0.20% |
More ▼
Data from 30 Jun 2023 - 02 May 2024Source: FactSet Research Systems Inc.
